STOCK TITAN

Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Baudax Bio, a pharmaceutical company focused on acute care products, announced that Gerri Henwood, the President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The corporate presentation will be available for on-demand listening starting September 13 at 7:00 a.m. ET, accessible on the company's website. Baudax Bio's key product, ANJESO, is a 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain. The company also has a pipeline of innovative pharmaceutical assets.

Positive
  • None.
Negative
  • None.

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

The presentation will be made available for on-demand listening beginning Monday, September 13, 2021 at 7:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be made available for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.

CONTACTS:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com


FAQ

When is Baudax Bio's presentation at the H.C. Wainwright conference?

Baudax Bio will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What time will Baudax Bio's presentation be available on-demand?

The on-demand presentation will be available starting September 13, 2021, at 7:00 a.m. Eastern Time.

How can I access Baudax Bio's presentation?

The presentation can be accessed on the 'Presentations' page within the investors section of the Baudax Bio website.

What is ANJESO, offered by Baudax Bio?

ANJESO is the first and only 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain.

What other products are in Baudax Bio's pipeline?

Baudax Bio's pipeline includes two novel neuromuscular blocking agents and a proprietary chemical reversal agent.

Baudax Bio, Inc.

OTC:BXRX

BXRX Rankings

BXRX Latest News

BXRX Stock Data

950.33k
43.59M
0.02%
2.68%
3.9%
Biotechnology
Healthcare
Link
United States
Malvern